Scottish Microbiology Reference Laboratories, Glasgow, UK.
ESCMID Study Group for C.difficile (ESGCD), Basel, Switzerland.
Adv Exp Med Biol. 2018;1050:245-254. doi: 10.1007/978-3-319-72799-8_14.
C. difficile is a major nosocomial pathogen, but is also increasingly recognised as an important diarrhoeal pathogen in the community, not always associated with antibiotics. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Clostridium difficile (ESGCD) is a group of clinicians and scientists from many European countries and further afield, who share a common interest in C. difficile. The aims of the Study Group are centred around raising the profile of CDI in humans and animals, fostering collaboration amongst centres in different European countries and providing a forum for discussing and disseminating information. One of the principal aims of the Study Group is to raise awareness of C. difficile infections in European hospitals. ESGCD has a particular interest in the development and dissemination of European guidance on prevention, diagnosis and treatment of CDI. This chapter will discuss the organisation of ESGCD within the ESCMID Study Group structure, the origins of the Study Group, the aims and objectives of the group, and will highlight some of the past and present activities of ESGCD in relation to these.
艰难梭菌是一种主要的医院病原体，但也越来越被认为是社区中一种重要的腹泻病原体，并不总是与抗生素有关。欧洲临床微生物学和传染病学会（ESCMID）艰难梭菌研究组（ESGCD）是一个由来自许多欧洲国家和其他地区的临床医生和科学家组成的团体，他们对艰难梭菌有着共同的兴趣。研究组的目标集中在提高人类和动物中 CDI 的知名度、促进不同欧洲国家中心之间的合作以及提供一个讨论和传播信息的论坛。研究组的主要目标之一是提高欧洲医院对艰难梭菌感染的认识。ESGCD 特别关注制定和传播有关 CDI 预防、诊断和治疗的欧洲指南。本章将讨论 ESGCD 在 ESCMID 研究组结构中的组织、研究组的起源、小组的目标和目的，并将重点介绍 ESGCD 过去和现在在这些方面的一些活动。
